WASHINGTON, Aug 9 (KUNA) -- The US Food and Drug Administration issued Tuesday an emergency use authorization (EUA) for the JYNNEOS vaccine "to allow healthcare providers to use the vaccine by intradermal injection for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection".
The FDA said in a statement "this will increase the total number of doses available for use by up to five-fold".
It added that "the EUA also allows for use of the vaccine in individuals younger than 18 years of age determined to be at high risk of monkeypox infection; in these individuals JYNNEOS is administered by subcutaneous injection".
FDA Commissioner Robert Califf said in this regard "in recent weeks the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand".
"By increasing the number of available doses, more individuals who want to be vaccinated against monkeypox will now have the opportunity to do so," he added.
According to the Department of Health and Human Services (HHS), to date, it has made over 1.1 million doses of the JYNNEOS vaccine available to order and, so far, has shipped more than 620,000 doses.
Last week, the US declared monkeypox to be a public health emergency. (end)